

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/380151658>

Hemochromatosis and HIV: Implications for Immune Senescence

Article · April 2024

CITATIONS

0

READS

5

1 author:



[Emmanuel Ifeanyi Obeagu](#)

Kampala International University (KIU)

1,630 PUBLICATIONS 21,998 CITATIONS

SEE PROFILE

Hemochromatosis and HIV: Implications for Immune Senescence

Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

Abstract

Hemochromatosis and HIV infection represent distinct yet intersecting conditions with significant implications for immune senescence, the gradual decline in immune function associated with aging. Hemochromatosis, characterized by excessive iron accumulation in tissues, and HIV infection, a chronic viral illness leading to progressive immune dysfunction, both contribute to immune dysregulation and accelerated aging of the immune system. This review explores the complex interplay between hemochromatosis, HIV infection, and immune senescence, highlighting the underlying mechanisms, clinical implications, and potential therapeutic strategies. Excess iron accumulation in hemochromatosis promotes oxidative stress, inflammation, and tissue damage, accelerating cellular aging and immune dysfunction. Iron overload affects immune cell function at multiple levels, including impairment of T cell and B cell responses, dysregulation of macrophage activity, and disruption of immune signaling pathways. Moreover, iron-mediated inflammation exacerbates immune senescence by promoting chronic activation of the innate and adaptive immune systems, contributing to the pathogenesis of age-related diseases and increasing susceptibility to infections in hemochromatosis patients. In HIV infection, chronic viral replication, and immune activation drive immune exhaustion, depletion of CD4⁺ T cells, and dysfunction of the immune system, leading to accelerated immune senescence. HIV-associated inflammation and viral persistence further exacerbate immune dysfunction and contribute to the premature aging of the immune system. The intersection of hemochromatosis and HIV infection exacerbates immune senescence, as iron overload and chronic inflammation synergistically

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

promote immune dysregulation and accelerated aging of the immune system in co-infected individuals.

Keywords: *Hemochromatosis, HIV, Immune Senescence, Iron Overload, Chronic Inflammation, Immune Dysfunction*

Introduction

Hemochromatosis, a hereditary disorder characterized by excessive iron absorption and accumulation in tissues, and HIV infection, a chronic viral illness leading to progressive immune dysfunction, are two distinct yet intersecting conditions with significant implications for immune senescence, the gradual decline in immune function associated with aging. Hemochromatosis, primarily caused by mutations in the HFE gene, disrupts iron homeostasis, resulting in iron overload in organs such as the liver, heart, and pancreas. In contrast, HIV infection targets the immune system, progressively compromising its function and leading to the development of acquired immunodeficiency syndrome (AIDS). While traditionally viewed as separate entities, emerging evidence suggests a complex interplay between hemochromatosis, HIV infection, and immune senescence, necessitating further exploration of their intersection. The aging process is characterized by changes in the immune system, collectively termed immune senescence, which contribute to increased susceptibility to infections, reduced vaccine efficacy, and higher rates of age-related diseases. Both hemochromatosis and HIV infection have been associated with accelerated immune senescence, albeit through different mechanisms. In hemochromatosis, iron overload promotes oxidative stress, inflammation, and tissue damage, accelerating cellular aging and impairing immune cell function. In HIV infection, chronic viral replication, immune activation, and exhaustion drive immune dysfunction and contribute to premature aging of the immune system. Understanding the intersection of hemochromatosis and HIV infection in the context of immune senescence is crucial for elucidating disease pathogenesis and identifying potential therapeutic targets.¹⁻³⁰

The immune system plays a central role in the pathogenesis of both hemochromatosis and HIV infection, with immune dysregulation and inflammation contributing to disease progression and clinical outcomes. In hemochromatosis, iron-mediated inflammation exacerbates tissue damage and organ dysfunction, leading to complications such as liver cirrhosis, cardiomyopathy, and diabetes mellitus. Similarly, in HIV infection, chronic immune activation and inflammation drive disease progression and increase the risk of non-AIDS-related comorbidities, including cardiovascular disease, neurocognitive impairment, and malignancies. The intersection of hemochromatosis and HIV infection may amplify immune dysregulation and accelerate immune senescence, posing additional challenges for affected individuals and clinicians. Despite advances in the management of hemochromatosis and HIV infection, the clinical implications of their intersection for immune senescence remain incompletely understood. Limited data exist on the impact of co-infection on immune function, disease progression, and treatment outcomes.

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

highlighting the need for further research in this area. Additionally, the development of targeted therapeutic interventions to mitigate immune senescence and improve clinical outcomes in co-infected individuals is warranted. By elucidating the complex interplay between hemochromatosis, HIV infection, and immune senescence, this review aims to provide insights into disease pathogenesis and inform the development of personalized therapeutic strategies for affected individuals.³¹⁻⁵⁰

Hemochromatosis and Immune Senescence

Hemochromatosis, characterized by excessive iron accumulation in tissues, is intricately linked to immune senescence, the gradual decline in immune function associated with aging. Iron overload in hemochromatosis promotes oxidative stress, inflammation, and tissue damage, accelerating cellular aging and impairing immune cell function. Iron-mediated inflammation exacerbates immune dysfunction by promoting chronic activation of the innate and adaptive immune systems, contributing to the pathogenesis of age-related diseases and increasing susceptibility to infections in hemochromatosis patients. The immune system plays a central role in the pathogenesis of hemochromatosis, with immune dysregulation and inflammation contributing to disease progression and clinical outcomes. Iron overload disrupts immune cell function at multiple levels, impairing T cell and B cell responses, dysregulating macrophage activity, and disrupting immune signaling pathways. Additionally, iron-mediated inflammation exacerbates tissue damage and organ dysfunction, leading to complications such as liver cirrhosis, cardiomyopathy, and diabetes mellitus. The intersection of hemochromatosis and immune senescence amplifies immune dysregulation, posing additional challenges for affected individuals and clinicians.⁵¹⁻⁷⁰

Despite advances in the management of hemochromatosis, the impact of iron overload on immune senescence remains incompletely understood. Limited data exist on the mechanisms driving immune dysfunction and the clinical implications of immune senescence in hemochromatosis patients. Further research is needed to elucidate the role of iron overload in accelerating immune aging and to develop targeted therapeutic interventions to mitigate immune dysfunction and improve clinical outcomes in affected individuals. By unraveling the complex interplay between hemochromatosis and immune senescence, this review aims to provide insights into disease pathogenesis and inform the development of personalized therapeutic strategies for affected individuals.⁷¹⁻⁸⁰

HIV Infection and Immune Senescence

HIV infection, a chronic viral illness characterized by progressive immune dysfunction, is closely associated with immune senescence, the gradual decline in immune function observed with aging. Chronic HIV replication and immune activation drive immune exhaustion, depletion of CD4⁺ T cells, and dysfunction of the immune system, leading to accelerated immune senescence. HIV-associated inflammation and viral persistence further exacerbate immune dysfunction and

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

contribute to the premature aging of the immune system. The immune system plays a central role in the pathogenesis of HIV infection, with immune dysregulation and inflammation driving disease progression and increasing the risk of non-AIDS-related comorbidities. Chronic immune activation and inflammation in HIV infection promote immune senescence by disrupting immune cell homeostasis, impairing immune surveillance, and compromising the ability to respond to pathogens and antigens. Moreover, the persistence of viral reservoirs and ongoing viral replication contribute to chronic immune activation, driving immune exhaustion and accelerating immune aging in HIV-infected individuals.⁸¹⁻⁹⁰

Intersection of Hemochromatosis and HIV

The intersection of hemochromatosis and HIV infection represents a complex interplay between two significant health challenges with far-reaching implications for affected individuals. Hemochromatosis, characterized by excessive iron accumulation in tissues, and HIV infection, a chronic viral illness leading to progressive immune dysfunction, present unique challenges when occurring simultaneously. The intersection of these conditions has implications for disease progression, treatment outcomes, and the development of non-AIDS-related comorbidities, warranting further investigation into their complex relationship. Iron overload in hemochromatosis and chronic inflammation in HIV infection interact in a bidirectional manner, exacerbating immune dysregulation and accelerating disease progression. Excess iron accumulation in tissues promotes oxidative stress, tissue damage, and inflammation, further impairing immune function and exacerbating HIV-associated immune activation. Conversely, chronic HIV replication and immune activation drive immune exhaustion and dysfunction, contributing to the dysregulation of iron metabolism and exacerbating iron overload in affected individuals. The clinical implications of the intersection of hemochromatosis and HIV infection are significant, impacting disease progression, treatment outcomes, and the development of non-AIDS-related comorbidities. Individuals co-infected with hemochromatosis and HIV may experience accelerated immune senescence, increased susceptibility to infections, and a higher risk of age-related diseases compared to those with either condition alone. Moreover, the management of co-infection presents unique challenges, including optimizing iron chelation therapy, managing drug interactions, and addressing the complex interplay between iron overload and immune dysfunction.⁹¹⁻¹²⁰

Clinical Implications and Therapeutic Strategies

The clinical implications of coexisting hemochromatosis and HIV infection are multifaceted, impacting disease progression, treatment outcomes, and the development of non-AIDS-related comorbidities. Individuals with both conditions may experience accelerated immune senescence, increased susceptibility to infections, and a higher risk of age-related diseases compared to those with either condition alone. Moreover, the management of co-infection presents unique challenges, including optimizing iron chelation therapy, managing drug interactions, and addressing the complex interplay between iron overload and immune dysfunction. Therapeutic strategies

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

targeting the intersection of hemochromatosis and HIV infection aim to mitigate immune dysfunction, reduce the burden of comorbidities, and improve clinical outcomes in affected individuals. Iron chelation therapy, such as deferoxamine, deferiprone, or deferasirox, may be utilized to reduce iron overload and oxidative stress in individuals with coexisting hemochromatosis and HIV infection. Hepcidin agonists or immunomodulatory agents targeting iron metabolism and inflammation pathways may also hold promise for mitigating immune dysfunction and improving clinical outcomes in co-infected individuals.¹²¹⁻¹⁴⁰

Optimizing antiretroviral therapy (ART) regimens is essential for suppressing viral replication, restoring immune function, and reducing the risk of HIV-associated comorbidities in co-infected individuals. Clinicians should consider potential drug interactions, toxicity, and adherence when selecting ART regimens for individuals with hemochromatosis and HIV infection. Moreover, lifestyle modifications, including dietary interventions, regular exercise, and avoidance of iron-rich foods and supplements, may help regulate iron metabolism and reduce oxidative stress in co-infected individuals, complementing pharmacological interventions and improving overall health outcomes. Additionally, personalized approaches that address both iron metabolism dysregulation and immune dysfunction may be necessary to optimize clinical care and improve outcomes in co-infected individuals. Targeted therapeutic interventions aimed at mitigating immune dysfunction and reducing the burden of comorbidities, such as cardiovascular disease, liver fibrosis, and neurocognitive impairment, are essential for improving clinical outcomes and quality of life in affected individuals. Further research is needed to elucidate the efficacy, safety, and long-term outcomes of these therapeutic approaches in co-infected individuals, highlighting the importance of interdisciplinary collaboration and translational research in optimizing care for individuals with both hemochromatosis and HIV infection.¹⁴¹⁻¹⁵⁸

Conclusion

The coexistence of hemochromatosis and HIV infection presents a complex clinical scenario with significant implications for disease progression, treatment outcomes, and the development of non-AIDS-related comorbidities. The intersection of these conditions exacerbates immune dysfunction, accelerates immune senescence, and increases the risk of age-related diseases in affected individuals. Therapeutic strategies targeting the intersection of hemochromatosis and HIV infection aim to mitigate immune dysfunction, reduce the burden of comorbidities, and improve clinical outcomes. Iron chelation therapy, hepcidin agonists, antiretroviral therapy optimization, and lifestyle modifications represent potential approaches to address both iron metabolism dysregulation and immune dysfunction in co-infected individuals. Personalized therapeutic interventions tailored to individual patient needs are essential for optimizing clinical care and improving outcomes in affected individuals.

References

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

1. Özdemir V. Public health in the age of genomics, 'Big Data' and massively collaborative global science. In *Routledge Handbook of Global Public Health in Asia* 2014: 74-90. Routledge.
2. Hinote BP, Wasserman JA. Social and behavioral science for health professionals. Rowman & Littlefield Publishers; 2019.
3. Pietrangelo A. Iron and the liver. *Liver international*. 2016 Jan; 36:116-23.
4. Daniłowicz-Szymanowicz L, Świątczak M, Sikorska K, Starzyński RR, Raczak A, Lipiński P. Pathogenesis, diagnosis, and clinical implications of hereditary hemochromatosis—the cardiological point of view. *Diagnostics*. 2021;11(7):1279.
5. Siddique A, Kowdley KV. The iron overload syndromes. *Alimentary pharmacology & therapeutics*. 2012 Apr;35(8):876-93.
6. Lal A. Iron in health and disease: an update. *The Indian Journal of Pediatrics*. 2020;87(1):58-65.
7. Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. *Annual Review of Physiology*. 2002;64(1):663-80.
8. Pantopoulos K. Inherited disorders of iron overload. *Frontiers in nutrition*. 2018; 5:103.
9. Pietrangelo A. Physiology of iron transport and the hemochromatosis gene. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 2002;282(3): G403-14.
10. Anderson GJ, Bardou-Jacquet E. Revisiting hemochromatosis: genetic vs. phenotypic manifestations. *Annals of translational medicine*. 2021;9(8).
11. Ayonrinde OT, Milward EA, Chua AC, Trinder D, Olynyk JK. Clinical perspectives on hereditary hemochromatosis. *Critical reviews in clinical laboratory sciences*. 2008;45(5):451-84.
12. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
13. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
14. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf).
15. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
16. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

17. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.1016/j.jphn.2022.129).
18. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
19. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
20. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
21. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.1016/j.jbio.2016.03.009).
22. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916.
[https://www.academia.edu/download/38320140/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
23. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
24. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
[links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://doi.org/10.1016/j.iosrjpbs.2017.04.015)
25. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
26. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.
[links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-](https://doi.org/10.1016/j.jbio.2016.03.009)

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.

27. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144.
https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf.
28. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4.
<links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf>
29. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
30. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.
31. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139.
<links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf>.
32. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):128-134.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
33. Walter O, Anaebio QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International.* 2022:29-34.
34. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International.* 2020;32(24):9-18.
35. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri.* 2022; 5 (8). 2022;137.
<links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf>.

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

36. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-142.DOI: [10.22192/ijarbs.2023.10.09.015](https://doi.org/10.22192/ijarbs.2023.10.09.015) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://www.research.sd publishers.net/id/eprint/2819/)
37. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134.DOI: [10.22192/ijarbs.2023.10.09.014](https://doi.org/10.22192/ijarbs.2023.10.09.014) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://www.research.sd publishers.net/id/eprint/2819/).
38. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](https://doi.org/10.22192/ijcrms.2017.03.05.014) https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfectd_with_HIV.pdf
39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
40. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183.DOI: **DOI:** [10.32474/JCCM.2020.02.000137](https://doi.org/10.32474/JCCM.2020.02.000137) [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://www.research.sd publishers.net/id/eprint/2819/).
41. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.
42. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth.* 2023 Jul 29;6(1):203-211. <http://research.sd publishers.net/id/eprint/2819/>.
43. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International.* 2021;33(57A):360-368.

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

44. Madakwe CC, Madakwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
45. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
46. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunyanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160.
<links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf>.
47. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
48. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI:
10.22192/ijcrops.2019.06.12.004
<links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf>.
49. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI:
10.22192/ijcrms.2023.09.02.002 <links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf>.
50. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33.
<links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf>.
51. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910.
[https://www.academia.edu/download/38320134/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
52. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
53. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.

<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.

54. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci*. 2014; 5:825-830.
55. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research*. 2014; 391:186-189.
56. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
57. Anderson GJ, Powell LW. HFE and non-HFE hemochromatosis. *International journal of hematology*. 2002; 76:203-207.
58. Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. *Annual Review of Physiology*. 2002;64(1):663-680.
59. Nelson JE, Kowdley KV. Non-HFE hemochromatosis: genetics, pathogenesis, and clinical management. *Current gastroenterology reports*. 2005; 7(1):71-80.
60. Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis, and treatment. *American journal of hematology*. 2006;81(3):202-209.
61. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-11.
62. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
63. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-108.
64. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-66.
65. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
66. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
67. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

- Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
68. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
 69. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
 70. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
 71. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
 72. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
 73. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
 74. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
 75. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health*. 2024;2(1):8-22.
 76. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology*. 2024;2(1):14-33.
 77. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine*. 2024;103(9): e37354.
 78. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*. 2024;2(1):1-3.
 79. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology*. 2024;2(1):34-46.
 80. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
 81. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

82. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: <http://www.journalijar.com>.;12(01).
83. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
84. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: <http://www.journalijar.com>.;12(01).
85. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
86. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
87. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
88. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
89. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
90. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
91. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
92. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-15.
93. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
94. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
95. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
96. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
97. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
98. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: <http://www.journalijar.com>.;12(01).

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

99. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):38-58.
100. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. *Elite Journal of HIV*. 2024;2(3):14-26.
101. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. *Elite Journal of Public Health*. 2024;2(1):52-63.
102. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
103. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
104. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
105. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. *Elite Journal of Nursing and Health Science*. 2024;2(3):59-72.
106. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*. 2024;2(2):5-15.
107. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
108. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
109. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. *Elite Journal of HIV*. 2024;2(2):60-73.
110. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*. 2024;2(1):10-22.
111. Obeagu EI, AmaezeAA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. *Elite Journal of Nursing and Health Science*. 2024;2(2):33-46.
112. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):11-24.
113. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.
114. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. *Elite Journal of Immunology*. 2024;2(3):33-44.

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

115. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. *Elite Journal of Immunology*. 2024;2(2):15-28.
116. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page*: <http://www.journalijar.com>;12(01).
117. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page*: <http://www.journalijar.com>;12(01).
118. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.
119. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
120. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. *Elite Journal of Haematology*, 2024; 2 (3):10-24.
121. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.
122. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*. 2024;2(1):51-64.
123. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):41-51.
124. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):24-36.
125. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. *Elite Journal of Immunology*. 2024;2(3):1-8.
126. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
127. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. *Elite Journal of Haematology*, 2024; 2 (3):42-57.
128. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. *Elite Journal of Scientific Research and Review*. 2024;2(1):1-6.
129. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
130. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
131. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. *Elite Journal of Health Science*. 2024;2(2):16-29.

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

132. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
133. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. *Elite Journal of Nursing and Health Science*. 2024;2(2):1-7.
134. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
135. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):9-19.
136. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):42-60.
137. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-105.
138. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. *Elite Journal of Haematology*, 2024; 2 (3):25-41.
139. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
140. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. *Elite Journal of HIV*. 2024;2(2):43-59.
141. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. *Elite Journal of Health Science*. 2024;2(3):23-35.
142. Obeagu EI, Obeagu GU, Ukibe NR, Oyejade SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. *Medicine*. 2024;103(2):e36937.
143. Mitterstiller AM, von Raffay L, Nairz M. Iron Deficiency, Anemia, and the Immune System. In *Nutritional Anemia 2022* Dec 16 (pp. 235-248). Cham: Springer International Publishing.
144. Ganesh GV, Mohanram RK. Metabolic reprogramming and immune regulation in viral diseases. *Reviews in medical virology*. 2022;32(2): e2268.
145. Obeagu EI, Obeagu GU. Exploration of Intricate Relationship between GATA-1 and Anemia in HIV. *Elite Journal of Haematology*, 2024; 2 (4):123-40.
146. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
147. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):84-99.

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71

148. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*. 2024;2(2):20-35.
149. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. *Elite Journal of Laboratory Medicine*. 2024;2(2):30-46.
150. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):30-40.
151. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. *Elite Journal of Public Health*. 2024;2(1):35-51.
152. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. *Elite Journal of Medicine*. 2024;2(3):48-59.
153. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. *Elite Journal of Immunology*. 2024;2(2):43-59.
154. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):14-32.
155. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. *Elite Journal of Scientific Research and Review*. 2024;2(1):17-41.
156. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine*. 2024;2(1):1-6.
157. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. *Elite Journal of Haematology*, 2024; 2 (3):.111-117.
158. Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. *Elite Journal of Medicine*, 2024; 2(5): 36-52

Citation: Obeagu EI. Hemochromatosis and HIV: Implications for Immune Senescence. *Elite Journal of Haematology*, 2024; 2(5): 55-71